

**Contact**

Troy Kehoe
JavaCulture Agency
630-803-4436

troy@javacultureagency.com

For Immediate Release**Long Grove Pharmaceuticals Launches Carboprost Tromethamine Injection, USP**

FDA-Approved Generic Expands Healthcare Options for Women, Continues Rapid Expansion for Emerging Generics Leader

ROSEMONT, Ill. – [Long Grove Pharmaceuticals®](https://www.longgrovepharma.com), founded in 2019 by strategic health care investor Water Street Healthcare Partners, today announced the launch of its second generic to market, Carboprost Tromethamine Injection, USP. The FDA-approved generic is now available.

Carboprost Tromethamine Injection, USP is AP Rated and is therapeutically equivalent to Pfizer’s Hemabate®. Long Grove Pharmaceuticals strives to provide differentiated generics to the market. Carboprost Tromethamine Injection, USP is available in a vial presentation, is TAA Compliant and made in Canada.

“The launch of Carboprost Tromethamine Injection continues Long Grove Pharmaceuticals’ commitment to rapid development of differentiated generics,” said Dan Robins, Ph.D., President & CEO of Long Grove Pharmaceuticals. “Our team has deep experience navigating the complex regulatory landscape and supply chain. We remain focused on bringing even more products like this to market as our portfolio expands.”

Long Grove Pharmaceuticals’ Carboprost Tromethamine Injection, USP marks the second product launch for the company in 2022 as it continues to emerge as a new U.S. generic pharmaceuticals leader. The company focuses on complex generics, including injectables and topical products, and is committed to improving customer choice while increasing access for patients.

For more information about Carboprost Tromethamine Injection, USP, including the boxed warning for dosing and administration guidance, please visit [longgrovepharma.com](https://www.longgrovepharma.com).

CARBOPROST TROMETHAMINE INJECTION, USP Important Safety Information**WARNINGS**

Carboprost tromethamine injection sterile solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. Carboprost tromethamine injection should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.

About Long Grove Pharmaceuticals®

Long Grove Pharmaceuticals was established in 2019 by Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. The company is part of Capstone Development Services, which has been developing products in partnership with the world’s premier pharmaceutical and medical device organizations since 2013. Combining decades of collective leadership experience with a portfolio of specialized, complex generic drug formulations, Long Grove Pharmaceuticals is poised to innovate across the generic injectable and topical markets.